Plus Therapeutics announces 1-for-25 reverse stock split

Plus Therapeutics announced that the company’s board of directors has approved a reverse stock split of its shares of common stock at a ratio of 1-for-25. The reverse stock split will become effective at 12:01 a.m. Eastern Time on April 2 and the company’s common stock will open for trading on Nasdaq Capital Market on a post-split basis on April 2 under the company’s existing trading symbol (PSTV). The reverse stock split is being implemented to increase the per share trading price of the company’s common stock for the purpose of ensuring a share price high enough to comply with the minimum $1.00 bid price requirement for continued listing on Nasdaq.